Quince Therapeutics Statistics
Share Statistics
Quince Therapeutics has 44.00M shares outstanding. The number of shares has increased by 0.95% in one year.
| Shares Outstanding | 44.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.81M |
| Failed to Deliver (FTD) Shares | 5.49K |
| FTD / Avg. Volume | 0.97% |
Short Selling Information
The latest short interest is 2.35M, so 5.33% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 5.33% |
| Short % of Float | 7.19% |
| Short Ratio (days to cover) | 2.27 |
Valuation Ratios
The PE ratio is -1.25 and the forward PE ratio is -5.42.
| PE Ratio | -1.25 |
| Forward PE | -5.42 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.46 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Quince Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.16.
| Current Ratio | 8.09 |
| Quick Ratio | 8.09 |
| Debt / Equity | 0.16 |
| Total Debt / Capitalization | 13.63 |
| Cash Flow / Debt | -1.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.37% and return on capital (ROIC) is -34.79%.
| Return on Equity (ROE) | -0.37% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -34.79% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -980.78K |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -197.00K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 72.03% in the last 52 weeks. The beta is 0.71, so Quince Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | 72.03% |
| 50-Day Moving Average | 1.48 |
| 200-Day Moving Average | 1.01 |
| Relative Strength Index (RSI) | 58.54 |
| Average Volume (20 Days) | 564.36K |
Income Statement
In the last 12 months, Quince Therapeutics had revenue of $0 and earned -$31.39M in profits. Earnings per share was $-0.84.
| Revenue | 0 |
| Gross Profit | -322.00K |
| Operating Income | -34.62M |
| Net Income | -31.39M |
| EBITDA | -31.26M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.84 |
Balance Sheet
The company has $20.75M in cash and $13.81M in debt, giving a net cash position of $6.94M.
| Cash & Cash Equivalents | 20.75M |
| Total Debt | 13.81M |
| Net Cash | 6.94M |
| Retained Earnings | -319.64M |
| Total Assets | 126.52M |
| Working Capital | 46.29M |
Cash Flow
In the last 12 months, operating cash flow was -$18.29M and capital expenditures -$160.00K, giving a free cash flow of -$18.45M.
| Operating Cash Flow | -18.29M |
| Capital Expenditures | -160.00K |
| Free Cash Flow | -18.45M |
| FCF Per Share | -0.5 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -41.38% |
| FCF Yield | -20.66% |
Analyst Forecast
The average price target for QNCX is $12, which is 491.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 491.1% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.77 |
| Piotroski F-Score | 2 |